NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: University Hospital, Bordeaux
Conditions: Renal Angiomyolipomas, Tuberous Sclerosis
Interventions: Propranolol
Countries: France
Treatment of angiomyolipomas is based on invasive techniques such as surgery or embolization. Development of anti-angiogenic therapies is a major and growing field of research in hypervascularized tumors. Angiomyolipomas have been shown to regress after prolonged treatment with mTOR inhibitors (Sirolimus), but with a large proportion of secondary effects. We showed recently that beta-blockers were able to induce regression of infantile hemagiomas. Consequently, we looked for and found, histologically, in a few cases of angiomyolipomas the presence of beta2 receptors. The aim of the study is to estimate if beta-blockers could induce regression or stabilization of renal angiomyolipomas in tuberous sclerosis in a pilot study.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * Tuberous sclerosis patients with one or several angiomyolipomas of a size of at least 4 cms. Exclusion Criteria: * Patients whom CT or MR scan shows one or several intra-lesional aneurisms requiring a preventive embolization. * Patients with a retroperitoneal hemorragic complication requiring a preventive embolization. * Patients whom biopsy will show an adenocarcinoma, hypertension non controlled, renal failure and severe liver. * Diabetic subjects insufficiently controlled. * Beta-blockers contra-indication. * Psychosis, severe mental disorder. * Patient already treated with beta-blockers or mTOR inhibitors. * Pregnant or nursing women.
- Bordeaux, France